On Monday 05/19/2025 the closing price of the BeiGene Ltd (spons. ADRs) share was $233.53 on BTT.
Compared to the opening price on Monday 05/19/2025 on BTT of $234.12, this is a drop of 0.25%.
BeiGene Ltd (spons. ADRs)'s market capitalization is $19.14 B by 99.25 M shares outstanding.
Is BeiGene stock a Buy, Sell or Hold?
BeiGene stock has received a consensus rating of buy. The average rating score is and is based on 18 buy ratings, 5 hold ratings, and 0 sell ratings.What was the 52-week low for BeiGene stock?
The low in the last 52 weeks of BeiGene stock was 141.60. According to the current price, BeiGene is 167.42% away from the 52-week low.What was the 52-week high for BeiGene stock?
The high in the last 52 weeks of BeiGene stock was 287.79. According to the current price, BeiGene is 82.37% away from the 52-week high.What are analysts forecasts for BeiGene stock?
The 23 analysts offering price forecasts for BeiGene have a median target of 273.34, with a high estimate of 350.00 and a low estimate of 152.50. The median estimate represents a 86.73 difference from the last price of 237.06.BeiGene Stock Snapshot
213.38
Bid
100.00
Bid Size
254.10
Ask
100.00
Ask Size
5/20/2025
Date
3:59 PM
Time
6,356.00
Volume
233.53
Prev. Close
234.12
Open
23.16 B
Market Cap in USD
99.25 M
Number of Shares
99.25 M
Total Number of Shares
233.11
Day Low
237.22
Day High
237.06
141.60
52 Week Low
287.79
52 Week High
237.06
0.00
Dividend in USD
0.00
Dividend Yield
99.11
Free Float in %
-6.12
EPS in USD
31.22
Book Value per Share in USD
-1.34
Cash Flow per Share in USD
BeiGene News More News
Historical Prices for BeiGene
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
BeiGene Analyst Data
Total Analysts: 23
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 152.50
Median: 273.34
Highest: 350.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
BeiGene Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/08/25 | RBC Capital Markets | Maintained Buy | $311 | |||
| 05/08/25 | Guggenheim | Maintained Buy | $350 | |||
| 04/28/25 | RBC Capital Markets | Maintained Buy | $312 | |||
| 04/24/25 | TD Securities | Maintained Buy | $334 | |||
| 04/21/25 | J.P. Morgan | Maintained Buy | $317 | |||
| 04/16/25 | Guggenheim | Maintained Buy | ||||
| 04/10/25 | Guggenheim | Maintained Buy | $348 | |||
| 04/07/25 | RBC Capital Markets | Maintained Buy | $312 | |||
| 02/28/25 | Macquarie Research | Maintained Buy | $313 | |||
| 07/09/24 | Bank of America Merrill Lynch | Maintained Hold | $152.5 | |||
| 04/08/24 | Bank of America Merrill Lynch | Maintained Hold | $164.300003051758 | |||
| 03/27/24 | Bernstein | Maintained Hold | $161 | |||
| 02/27/24 | Guggenheim | Maintained Buy | $345 | |||
| 02/06/24 | J.P. Morgan | Maintained Buy | $185 | |||
| 10/26/23 | Citigroup Corp. | Maintained Buy | $285 | |||
| 09/21/23 | Citigroup Corp. | Maintained Buy | $290 | |||
| 09/20/23 | Bank of America Merrill Lynch | Maintained Hold | $212 | |||
| 09/12/23 | Macquarie Research | Maintained Buy | $259 | |||
| 09/12/23 | RBC Capital Markets | Maintained Buy | $259 | |||
| 08/29/23 | Morgan Stanley | Maintained Buy | $319 | |||
| 08/17/23 | Jefferies & Company Inc. | Maintained Buy | $287 | |||
| 08/07/23 | J.P. Morgan | Maintained Buy | $300 | |||
| 07/17/23 | Citigroup Corp. | Maintained Buy | $275 | |||
| 06/30/23 | Bernstein | Downgraded to Hold | $196 |
BeiGene Estimates* in USD
| 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|
| Revenue | 5,077 | 6,151 | 7,204 | 7,920 | 8,662 |
| Dividend | 0.00 | 0.35 | 1.30 | - | - |
| Dividend Yield (in %) | 0.00 % | 0.15 % | 0.56 % | - | - |
| EPS | 1.50 | 5.50 | 10.15 | 11.82 | 14.26 |
| P/E Ratio | 155.38 | 42.47 | 22.99 | 19.75 | 16.37 |
| EBIT | 104 | 562 | 1,301 | 1,715 | 2,171 |
| EBITDA | 256 | 736 | - | 2,857 | 4,287 |
| Net Profit | 114 | 515 | 1,110 | - | - |
| Net Profit Adjusted | 258 | 590 | - | - | - |
| Pre-Tax Profit | 174 | 611 | - | - | - |
| Pre-Tax Profit Reported | 241 | 774 | 1,383 | 1,600 | - |
| EPS (Non-GAAP) ex. SOE | - | 5.22 | 10.74 | 13.13 | 10.60 |
| EPS (GAAP) | 1.00 | 5.26 | 10.28 | 10.68 | 9.18 |
| Gross Income | 4,332 | 5,255 | 6,158 | 6,838 | 7,760 |
| Cash Flow from Investing | -333 | -351 | - | - | - |
| Cash Flow from Operations | 323 | 924 | - | - | - |
| Cash Flow from Financing | -24 | -15 | -5 | 49 | 11 |
| Cash Flow per Share | 2.39 | 7.22 | 12.74 | 17.68 | - |
| Free Cash Flow | 98 | 683 | 1,450 | 1,807 | 2,611 |
| Free Cash Flow per Share | 1.62 | 6.34 | 9.30 | - | - |
| Book Value per Share | 31.70 | 37.45 | 50.56 | 63.15 | - |
| Net Debt | -1,529 | -2,137 | -3,524 | -5,297 | - |
| Research & Development Exp. | 2,108 | 2,297 | 2,424 | 2,536 | 2,637 |
| Capital Expenditure | 271 | 284 | 290 | 453 | 491 |
| Selling, General & Admin. Exp. | 2,077 | 2,297 | 2,396 | 2,276 | 2,322 |
| Shareholder’s Equity | 3,587 | 4,334 | - | - | 13,002 |
| Total Assets | 6,308 | 7,310 | - | 12,579 | 16,974 |
|
Previous Quarter ending 03/31/25 |
Current Quarter ending 06/30/25 |
Next Quarter ending 09/30/25 |
Current Year ending 12/31/25 |
Next Year ending 12/31/26 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | - | 13 | 13 | 34 | 34 |
| Average Estimate | - | 0.196 USD | 0.336 USD | 1.502 USD | 5.495 USD |
| Year Ago | - | -1.150 USD | -1.146 USD | -6.124 USD | - |
| Publish Date | - | 8/22/2025 | 11/6/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | - | 12 | 12 | 37 | 37 |
| Average Estimate | - | 1,226 USD | 1,291 USD | 5,077 USD | 6,151 USD |
| Year Ago | - | 929 USD | 1,002 USD | 3,810 USD | - |
| Publish Date | - | 8/22/2025 | 11/6/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales | 3,810.24 | 2,458.78 | 1,415.92 | 1,176.28 | 308.87 | 428.21 | 198.22 |
| Change of sales in % | 54.96 | 73.65 | 20.37 | 280.83 | -27.87 | 116.03 | -16.85 |
| Gross profit on sales | 3,091.83 | 1,994.92 | 1,066.39 | 965.89 | 206.43 | 338.41 | 159.62 |
| Gross profit on sales change in % | 54.98 | 87.07 | 10.41 | 367.90 | -39.00 | 112.01 | -30.24 |
| Operating income | -568.20 | -1,207.74 | -1,788.00 | -1,438.74 | -1,657.68 | -959.89 | -705.77 |
| Operating income change in % | 52.95 | 32.45 | -24.28 | 13.21 | -72.69 | -36.01 | -616.83 |
| Income before tax | -533.00 | -825.84 | -1,961.04 | -1,438.59 | -1,618.19 | -943.59 | -689.83 |
| Income before tax change in % | 35.46 | 57.89 | -36.32 | 11.10 | -71.49 | -36.79 | -657.52 |
| Income after tax | -644.79 | -881.71 | -2,003.82 | -1,413.35 | -1,596.91 | -948.63 | -673.77 |
| Income after tax change in % | 26.87 | 56.00 | -41.78 | 11.49 | -68.34 | -40.79 | -623.67 |
Balance Sheet in Mio. USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 2,592.89 | 2,267.95 | 1,995.94 | 2,402.96 | 1,731.51 | 633.93 | 496.04 |
| Long-term liabilities per share | 3.56 | 4.44 | 5.14 | - | 6.63 | 4.50 | 3.55 |
| Equity | 3,332.22 | 3,537.33 | 4,383.36 | 6,242.99 | 3,869.24 | 978.36 | 1,753.65 |
| Equity change in % | -5.80 | -19.30 | -29.79 | 61.35 | 302.12 | -44.68 | 159.66 |
| Balance sheet total | 5,925.12 | 5,805.28 | 6,379.29 | 8,645.95 | 5,600.76 | 1,612.29 | 2,249.68 |
| Balance sheet total change in % | 2.06 | -9.00 | -26.22 | 54.37 | 247.38 | -28.33 | 114.90 |
Key Data in USD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 36.19 | 23.55 | 13.73 | 12.68 | 3.70 | 7.13 | 3.32 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - | - | - | - |
| P/E ratio (year end quote, diluted EPS) | - | - | - | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 56.24 | 60.93 | 68.71 | 72.21 | 69.08 | 60.68 | 77.95 |
| Debt ratio in % | 43.76 | 39.07 | 31.29 | 27.79 | 30.92 | 39.32 | 22.05 |
BeiGene Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Wang Xiaodong | 05/12/2025 | 200.00 | n/a | 225.68 | Sell | No |
| Wang Xiaodong | 05/12/2025 | 10,221.00 | 31,539.00 | 222.83 | Sell | No |
| Wang Xiaodong | 05/12/2025 | 10,104.00 | 200.00 | 224.32 | Sell | No |
| Wang Xiaodong | 05/12/2025 | 21,235.00 | 10,304.00 | 223.41 | Sell | No |
| Wang Xiaodong | 05/12/2025 | 41,760.00 | 41,760.00 | 6.50 | Buy | No |
| OYLER JOHN | 05/08/2025 | 1,990,603.00 | 8,163,437.00 | 17.85 | Sell | No |
| OYLER JOHN | 05/08/2025 | 4,055,415.00 | 10,154,040.00 | 0.50 | Buy | No |
| Wang Xiaodong | 04/13/2025 | 1,592.00 | 6,300.00 | 244.56 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 365.00 | n/a | 249.45 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 6,398.00 | 7,892.00 | 243.41 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 2,229.00 | 29,331.00 | 241.51 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 805.00 | 39,960.00 | 238.48 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 1,475.00 | 900.00 | 247.46 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 1,869.00 | 2,375.00 | 246.40 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 2,056.00 | 4,244.00 | 245.56 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 5,516.00 | 31,560.00 | 240.41 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 2,884.00 | 37,076.00 | 239.51 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 995.00 | 40,765.00 | 237.56 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 15,041.00 | 14,290.00 | 242.59 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 535.00 | 365.00 | 248.90 | Sell | No |
| Wang Xiaodong | 04/13/2025 | 41,760.00 | 41,760.00 | 6.50 | Buy | No |
| Wu Xiaobin | 03/31/2025 | 28,253.00 | 23,668.00 | 280.31 | Sell | No |
| Wu Xiaobin | 03/31/2025 | 5,083.00 | n/a | 283.79 | Sell | No |
| Wu Xiaobin | 03/31/2025 | 6,364.00 | 17,304.00 | 281.67 | Sell | No |
| Wu Xiaobin | 03/31/2025 | 12,221.00 | 5,083.00 | 282.76 | Sell | No |
BeiGene Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2024 | BeiGene Ltd (spons. ADRs) | 0.00 | 0.00 | USD |
| 2023 | BeiGene Ltd (spons. ADRs) | 0.00 | 0.00 | USD |
| 2022 | BeiGene Ltd (spons. ADRs) | 0.00 | 0.00 | USD |
| 2021 | BeiGene Ltd (spons. ADRs) | 0.00 | 0.00 | USD |
| 2020 | BeiGene Ltd (spons. ADRs) | 0.00 | 0.00 | USD |
| 2019 | BeiGene Ltd (spons. ADRs) | 0.00 | 0.00 | USD |
| 2018 | BeiGene Ltd (spons. ADRs) | 0.00 | 0.00 | USD |
| 2017 | BeiGene Ltd (spons. ADRs) | 0.00 | 0.00 | USD |
| 2016 | BeiGene Ltd (spons. ADRs) | 0.00 | 0.00 | USD |
| 2015 | BeiGene Ltd (spons. ADRs) | - | - | USD |
| 2014 | BeiGene Ltd (spons. ADRs) | - | - | USD |
| 2013 | BeiGene Ltd (spons. ADRs) | - | - | USD |
*Yield of the Respective Date
BeiGene Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Annual General Meeting | -6.124 USD | Annual General Meeting | 05/21/2025 |
| Earnings Report | 0.196 USD | Q2 2025 Earnings Release | 08/22/2025 |
| Earnings Report | 0.336 USD | Q3 2025 Earnings Release | 11/06/2025 |
| Earnings Report | 0.895 USD | Q4 2025 Earnings Release | 04/01/2026 |
| Earnings Report | 0.599 USD | Q1 2026 Earnings Release | 04/30/2026 |
BeiGene Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 0.011 USD | Q1 2025 Earnings Release | 05/07/2025 |
| Earnings Report | -1.429 USD | Q4 2024 Earnings Release | 03/27/2025 |
| Earnings Report | -1.146 USD | Q3 2024 Earnings Release | 11/12/2024 |
| Earnings Report | -1.150 USD | Q2 2024 Earnings Release | 08/27/2024 |
| Annual General Meeting | -8.447 USD | Annual General Meeting | 06/05/2024 |
| Earnings Report | -2.409 USD | Q1 2024 Earnings Release | 05/08/2024 |
| Earnings Report | -3.532 USD | Q4 2023 Earnings Release | 02/26/2024 |
| Earnings Report | 2.014 USD | Q3 2023 Earnings Release | 11/09/2023 |
| Earnings Report | -3.643 USD | Q2 2023 Earnings Release | 08/25/2023 |
| Annual General Meeting | -19.429 USD | Annual General Meeting | 06/15/2023 |
| Earnings Report | -3.345 USD | Q1 2023 Earnings Release | 05/04/2023 |
| Earnings Report | -4.292 USD | Q4 2022 Earnings Release | 03/29/2023 |
| Earnings Report | -5.388 USD | Q3 2022 Earnings Release | 11/09/2022 |
| Earnings Report | -5.559 USD | Q2 2022 Earnings Release | 08/26/2022 |
| Annual General Meeting | -15.233 USD | Annual General Meeting | 06/22/2022 |
| Earnings Report | -4.238 USD | Q1 2022 Earnings Release | 05/05/2022 |
| Earnings Report | -6.163 USD | Q4 2021 Earnings Release | 03/30/2022 |
BeiGene Profile
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.